Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients.

Renske H OlieRachelle R K HensgensPetal A H M WijnenLeo F VeenstraBianca T A de GreefMinka J A VriesPaola E J van der MeijdenJurriën M Ten BergHugo Ten CateOtto BekersYvonne M C Henskens

Published in: Journal of clinical medicine (2021)

For VerifyNow and LTA, the on-treatment platelet reactivity in clopidogrel-treated patients correlates well with the underlying CYP2C19 polymorphism. For Multiplate, no major effect of genetic background could be shown, and effects of other (patient-related) variables prevail. Thus, besides differences in test principles and the influence of patient-related factors, the disagreement between PFTs is partly explained by differential effects of the CYP2C19 genotype.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
acute coronary syndrome
chronic kidney disease
prognostic factors
peritoneal dialysis
percutaneous coronary intervention
case report
patient reported outcomes
dna methylation
atrial fibrillation